Search Results - "Owonikoko, T K"

Oncogenic role of EAPII in lung cancer development and its activation of the MAPK-ERK pathway by Li, C, Fan, S, Owonikoko, T K, Khuri, F R, Sun, S-Y, Li, R

“…Cancer progression involves multiple complex and interdependent steps, including progressive proliferation, angiogenesis and metastases. The complexity of…”
Get full text

A phase 1 Bayesian dose selection study of bortezomib and sunitinib in patients with refractory solid tumor malignancies by Harvey, R D, Owonikoko, T K, Lewis, C M, Akintayo, A, Chen, Z, Tighiouart, M, Ramalingam, S S, Fanucchi, M P, Nadella, P, Rogatko, A, Shin, D M, El-Rayes, B, Khuri, F R, Kauh, J S

“…Background: This phase 1 trial utilising a Bayesian continual reassessment method evaluated bortezomib and sunitinib to determine the maximum tolerated dose…”
Get full text

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial by Weiss, J.M., Csoszi, T., Maglakelidze, M., Hoyer, R.J., Beck, J.T., Domine Gomez, M., Lowczak, A., Aljumaily, R., Rocha Lima, C.M., Boccia, R.V., Hanna, W., Nikolinakos, P., Chiu, V.K., Owonikoko, T.K., Schuster, S.R., Hussein, M.A., Richards, D.A., Sawrycki, P., Bulat, I., Hamm, J.T., Hart, L.L., Adler, S., Antal, J.M., Lai, A.Y., Sorrentino, J.A., Yang, Z., Malik, R.K., Morris, S.R., Roberts, P.J., Dragnev, K.H.

“…Chemotherapy-induced damage of hematopoietic stem and progenitor cells (HSPC) causes multi-lineage myelosuppression. Trilaciclib is an intravenous CDK4/6…”
Get full text

Role of Ku70 in deubiquitination of Mcl-1 and suppression of apoptosis by Wang, B, Xie, M, Li, R, Owonikoko, T K, Ramalingam, S S, Khuri, F R, Curran, W J, Wang, Y, Deng, X

“…Mcl-1 is a unique antiapoptotic Bcl2 family member with a short half-life due to its rapid turnover through ubiquitination. We discovered that Ku70, a DNA…”
Get full text

Nivolumab (nivo) plus ipilimumab (ipi), nivo, or placebo (pbo) as maintenance therapy in patients (pts) with extensive disease small cell lung cancer (ED-SCLC) after first-line (1L) platinum-based chemotherapy (chemo): Results from the double-blind, randomized phase III CheckMate 451 study by Owonikoko, T.K., Kim, H.R., Govindan, R., Ready, N., Reck, M., Peters, S., Dakhil, S.R., Navarro, A., Rodriguez-Cid, J., Schenker, M., Lee, J.S., Gutierrez, V., Percent, I., Morgensztern, D., Fairchild, J., Baudelet, C., Park, K.

Get full text

Trilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Sorrentino, J.A., Lai, A., Weiss, J.M., Dragnev, K.H., Owonikoko, T.K., Adler, S., Antal, J.M., Malik, R.K., Roberts, P.J.

Get full text

Inhibition of B-Raf/MEK/ERK signaling suppresses DR5 expression and impairs response of cancer cells to DR5-mediated apoptosis and T cell-induced killing by Oh, Y-T, Deng, J, Yue, P, Owonikoko, T K, Khuri, F R, Sun, S-Y

“…Inhibition of B-Raf/MEK/ERK signaling is an effective therapeutic strategy against certain types of cancers such as melanoma and thyroid cancer. While…”
Get full text

Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data by Owonikoko, T.K., Papadopoulos, K.P., Gil-Martin, M., Moreno, V., Salama, A.K., Calvo, E., Safran, H., González-Martín, A., Aljumaily, R., Mahadevan, D., Niu, J., Kal Mohan, K., Li, J., Stankevich, E., Mathias, M., Lowy, I., Fury, M.G., Babiker, H.M.

Get full text

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) by Babiker, H.M., Brana, I., Mahadevan, D., Owonikoko, T.K., Calvo, E., Rischin, D., Moreno, V., Papadopoulos, K.P., Crittenden, M., Formenti, S., Giralt, J., Garrido Lopez, P., Hervás Morón, A., Mohan, K.K., Fury, M.G., Lowy, I., Stankevich, E., Feng, M., Li, J., Mathias, M.

Get full text

Sites of metastasis and association with clinical outcome (CO) in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Shabto, J.M., Martini, D.J., Liu, Y., Lewis, C., Collins, H.H., Akce, M., Kissick, H., Carthon, B.C., Shaib, W.L., Alese, O.B., Steuer, C.E., Wu, C., Lawson, D.H., Kudchadkar, R., Master, V., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D.

Get full text

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO) by Bilen, M.A., Martini, D.J., Shabto, J.M., Liu, Y., Khan, A.I., Williams, M.A., Lewis, C., Collins, H.H., Kissick, H., Carthon, B.C., Akce, M., Shaib, W.L., Alese, O.B., Lawson, D.H., Kudchadkar, R., El-Rayes, B., Ramalingam, S.S., Owonikoko, T.K., Harvey, R.D., Master, V.A.

Get full text

Trilaciclib (T) decreases multi-lineage myelosuppression in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Dragnev, K.H., Owonikoko, T.K., Csoszi, T., Maglakelidze, M., Beck, J.T., Domine Gomez, M., Lowczak, A., Fulop, A., Hoyer, R.J., Hanna, W., Lowry, P., Aljumaily, R., Chiu, V.K., Bulat, I., Yang, Z., Roberts, P.J., Antal, J.M., Malik, R.K., Morris, S.R., Weiss, J.M.

Get full text

Analysis of liver-directed therapies in U.S. cancer patients by Alese, O B, Kim, S, Chen, Z, Ramalingam, S S, Owonikoko, T K, El-Rayes, B F

“…The liver is a common site of primary and metastatic cancer. Liver-directed therapies are commonly used to treat cancer involving the liver. We report on the…”
Get full text

Colorectal neoplasms: a retrospective study by Elesha, S O, Owonikoko, T K

“…A total of 254 cases of colorectal neoplasms were studied. A male predominance was noted with both benign and malignant neoplasms (M:F of 4.6:1 and 1.1:1…”
Get more information

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma by Migden, Michael R, Rischin, Danny, Schmults, Chrysalyne D, Guminski, Alexander, Hauschild, Axel, Lewis, Karl D, Chung, Christine H, Hernandez-Aya, Leonel, Lim, Annette M, Chang, Anne Lynn S, Rabinowits, Guilherme, Thai, Alesha A, Dunn, Lara A, Hughes, Brett G.M, Khushalani, Nikhil I, Modi, Badri, Schadendorf, Dirk, Gao, Bo, Seebach, Frank, Li, Siyu, Li, Jingjin, Mathias, Melissa, Booth, Jocelyn, Mohan, Kosalai, Stankevich, Elizabeth, Babiker, Hani M, Brana, Irene, Gil-Martin, Marta, Homsi, Jade, Johnson, Melissa L, Moreno, Victor, Niu, Jiaxin, Owonikoko, Taofeek K, Papadopoulos, Kyriakos P, Yancopoulos, George D, Lowy, Israel, Fury, Matthew G

“…Among patients with advanced cutaneous squamous-cell carcinoma, the PD-1 inhibitor cemiplimab induced a response in approximately half the patients and was…”
Get full text

1193PDAnalysis of tumour hyperprogression (HP) with nivolumab (Nivo) in randomized, placebo (Pbo)-controlled trials by Reck, M, Feng, Y, Kim, H R, Plautz, G, Kang, Y-K, Owonikoko, T K, Nghiem, P, Sheng, J

“…Abstract Background Tumor HP has been suggested to occur in some patients with solid tumors subsequent to PD-1/L1 inhibitor monotherapy; however, reports are…”
Get full text

Feasibility of Using FDG in the Stereotactic Ablative Setting for Tracked Dose Delivery With BgRT: Results from a Prospective Study of Serial Inter-Fraction PET/CTs by Da Silva, A., Olcott, P., Tian, S., Yang, X., Sethi, I., Shirvani, S.M., Mazin, S., Owonikoko, T.K., Bradley, J.D., Schuster, D.M., Higgins, K.A.

“…Biology-guided radiotherapy (BgRT) is a new radiation modality that utilizes real-time limited time sampled FDG PET images of a tumor to deliver a dynamically…”
Get full text

1862PDImpact of lung metastasis on overall survival (OS) in the phase III SELECT study with lenvatinib (LEN) in patients (pts) with radioiodine refractory differentiated thyroid cancer (RR-DTC) by Tahara, M, Kiyota, N, Hoff, A O, Badiu, C, Owonikoko, T K, Dutcus, C E, Suzuki, T, Ren, M, Misir, S, Wirth, L J

“…Abstract Background In the randomized phase III SELECT study, LEN demonstrated a significant prolongation of progression-free survival compared with placebo…”
Get full text

NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer by Higgins, K.A., Hu, C., Stinchcombe, T.E., Jabbour, S.K., Kozono, D.E., Owonikoko, T.K., Movsas, B., Ritter, T.A., Xiao, C., Williams, T.M., Welsh, J.W., Simko, J., Wang, X., Mohindra, N.A., Hsu, C.C., Bradley, J.D.

“…Clinical outcomes for limited stage small cell lung cancer (LS-SCLC) remain suboptimal. Standard of care chemoradiation with platinum/etoposide and thoracic…”
Get full text

1671PTrilaciclib (trila) preserves and enhances immune system function in extensive-stage small cell lung cancer (ES-SCLC) patients receiving first-line chemotherapy by Sorrentino, J A, Lai, A, Weiss, J M, Dragnev, K H, Owonikoko, T K, Adler, S, Antal, J M, Malik, R K, Roberts, P J

Get full text